MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Country |
 USA |
IPO year |
2016 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
22 M |
Market Cap[1] |
$ 2.64 M |
EBITDA (LTM) |
$ -43.9 M |
P/E (LTM) |
- |
P/S (LTM) |
0.16 |
EPS (LTM) |
-1.94 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Celldex Therapeutics
CLDX
|
$ 34.83 | 2.85 % | $ 2.31 B | Nasdaq Global Select Market | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 4.3 | 8.31 % | $ 10.3 B | Nasdaq Capital Market |  Australia |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Akari Therapeutics, Plc
AKTX
|
$ 5.98 | 16.72 % | $ 403 B | Nasdaq Capital Market |  Britain |
 |
Aligos Therapeutics
ALGS
|
$ 6.69 | -12.73 % | $ 66.1 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 307.49 | -3.95 % | $ 40.3 B | Nasdaq Global Select Market,SPB | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 22.72 | 4.17 % | $ 1.06 B | Nasdaq Global Select Market | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
BioNTech SE
BNTX
|
$ 103.65 | 1.5 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.09 | 0.32 % | $ 5.09 M | NYSE American |  Israel |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
BioXcel Therapeutics
BTAI
|
$ 1.17 | 9.67 % | $ 14.3 M | Nasdaq Global Select Market,SPB | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Akebia Therapeutics
AKBA
|
$ 1.41 | 5.19 % | $ 363 M | Nasdaq Global Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.33 | 1.69 % | $ 463 M | Nasdaq Global Market | USA |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
$ 24.54 | 1.43 % | $ 3.12 B | Nasdaq Global Select Market,SPB | USA |
 |
Burford Capital Limited
BUR
|
$ 4.89 | 4.71 % | $ 792 M | NYSE | Britain |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Cabaletta Bio
CABA
|
$ 3.33 | -5.4 % | $ 335 M | Nasdaq Global Select Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.67 | 3.5 % | $ 444 M | Nasdaq Global Select Market | Britain |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Cidara Therapeutics
CDTX
|
- | - | $ 1.41 B | Nasdaq Global Market | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.87 | 1.44 % | $ 5.85 M | Nasdaq Capital Market | USA |
 |
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.